This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEB6R0AQ_M.jpg
Thus, biotech companies are under pressure to develop effective drugs to combat the disease. They have been conducting multiple clinical trials to extend cancer patients’ survival rates and duration of response and are adopting advanced technologies in immunotherapies to capitalize on the heightened need for cancer treatments. The global interventional oncology market is expected to grow at a 6.8% CAGR over the next five years to hit $2.9 billion by 2026. In fact, positive results from clinical trials reported by multiple biotech companies have boosted investor optimism regarding the growth potential of this industry. This is evident in Loncar Cancer Immunotherapy ETF’s (CNCR) 7.2% returns over the past month versus SPDR S&P 500 Trust ETF’s (SPY) 1.4% gains.
Given this backdrop, we believe AstraZeneca PLC (AZN), Amgen Inc . (NASDAQ:AMGN), Incyte Corporation (INCY), and Champions Oncology, Inc. (CSBR) could be ideal investment bets now.
